ScripWhile President Trump’s efforts to downsize the US Food and Drug Administration and plans to impose tariffs are currently spooking biopharma investors, some companies were able to defy the gloomy sent
ScripJohnson & Johnson unveiled its second atopic dermatitis-focused deal this month on 28 May, paying $1.25bn in cash to acquire a subsidiary of Numab Therapeutics AG that houses a Phase II-ready bispe
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Ono Calls On PRISM For Oncology Di
ScripAmid a longer than expected industry downturn, Chinese pharma firms with a solid commercial footing in their home market are now turning to acquiring domestic rights to novel drug assets from their bi